October 26, 2025
Article
The Beamion LUNG-1 study showed that first-line Hernexeos had benefit for patients with HER2-mutated NSCLC.
October 20, 2025
Enhertu plus Perjeta improved progression-free survival versus THP in patients with HER2-positive advanced or metastatic breast cancer across subgroups.
October 19, 2025
Adding Tecentriq to chemo resulted in survival outcomes comparable to placebo plus chemo in patients with advanced or recurrent endometrial cancer.
October 18, 2025
In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.
Cancer From A Patient’s Point of View
Hernexeos Effective in HER2-Mutated NSCLC
Anemia Management in Myelofibrosis: Survival and Quality of Life
Simple Ways for Patients With Cancer to Start Exercising